DS
BLPH

DRW Securities’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

DRW Securities’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,000
Closed -$254K – 114
2018
Q2 		$254K Buy
7,000
+2,333
+50% +$80.7K 0.02% 57
2018
Q1 		$146K Buy
+4,667
New +$148K 0.01% 135

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DRW Securities's BLPH Position: Q3 2018 in Review

DRW Securities sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2018, closing a stake of 7,000 shares — an estimated $254K sold.

DRW Securities first reported a position in BLPH in Q1 2018 and held it in 2 quarters. The position peaked at $254K in Q2 2018. 30 funds tracked by Wall St. Rank hold BLPH as of Q3 2018.

  • DRW Securities reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • DRW Securities sold 7,000 Bellerophon Therapeutics, Inc. shares in Q3 2018, an estimated $254K.
  • DRW Securities first reported a position in Bellerophon Therapeutics, Inc. in Q1 2018 and held it in 2 quarters.
  • DRW Securities's Bellerophon Therapeutics, Inc. position peaked at $254K in Q2 2018.
  • 30 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.